China biotech RiboX reveals first data of circular RNA therapies in people
Biotech investors and pharma companies have poured billions into three Boston-region startups competing to develop a next-generation version of mRNA technology that could make for more durable and potent therapies. But now a relatively
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.